Short answer
Tonix Pharmaceuticals Holding Corp. (TNXP) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $14M (up 577.9% year over year) with net income of −$41M.
Q2 2026 key financials · XBRL
- Revenue
- $14M
- +577.9% YoY · +96.9% QoQ
- Net income
- −$41M
- −43.4% YoY · −0.9% QoQ
- Operating margin
- -314.1%
- EPS (diluted)
- −$2.39
- +39.6% YoY · +18.4% QoQ
Source: XBRL data from the Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 10-Q on SEC EDGAR. USD.
Tonix Pharmaceuticals Holding Corp. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $13.5M vs $2.0M, up $11.5M YoY, driven by TONMYA launch
- TONMYA best-performing product, $11.0M revenue; Tosymra lowest, $0.6M
- Operating loss $42.5M vs $28.3M; net loss $40.6M vs $28.3M
- Cash $176.2M at June 30; operating cash use $84.6M vs $31.4M YoY
- Funding outlook: resources expected through early Q2 2027, with substantial going-concern doubt beyond one year
Risk Factors
- No material changes identified; risks cross-referenced to December 31, 2025 Form 10-K
- Additional unknown or currently immaterial risks potentially affecting financial position, results, or cash flows
- No new regulatory or compliance risk disclosed for quarter ended June 30, 2026
- No equity sales, securities purchases, or senior-security defaults during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tonix Pharmaceuticals Holding Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.